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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of pharmacological, behaviour change, and organisational interventions compared to comparator intervention in
preventing diabetes among people with mental illness in LMICs.
B A C K G R O U N D
Mental disorders have been identified as substantial and increasing
sources of global disease burden. They are now one of the leading
causes of disability worldwide, accounting for almost a quarter
of all years lived with a disability (Murray 2012; Vos 2012) and
significantly increased mortality (Correll 2017; Lawrence 2010;
Mitchell 2013; Scott 2009). Studies have repeatedly reported a
10 to 20 years mortality gap for people with mental illness, and,
despite an overall improvement in life expectancy in recent years,
the absolute mortality gap between people with mental illness and
those without, is actually widening (Chesney 2014; Hayes 2017;
Olfson 2015; Saha 2007). Studies from low- and middle-income
countries (LMIC) show a similar pattern of increased mortality
but with an even greater reduction in life expectancy than in high-
income countries (Dube 1984; Fekadu 2015; Kurihara 2011;
Mogga 2006). However, only 0.5 to 2% of the health budget is
allocated for the prevention and treatment of mental disorders in
LMICs (Stubbs 2017), and mental illness remains a major health
challenge in these countries (Rathod 2017).
A considerable proportion of the increased morbidity and mor-
tality experienced by people with mental disorders is driven,
not by the mental illness, but by comorbid physical illnesses
(Hayes 2017). The vast majority of deaths (around 80%) are due
to preventable physical illnesses, most commonly cardiovascular,
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metabolic and respiratory diseases, and infections (Correll 2017;
Crump 2013; Laursen 2011). Mental and physical disorders have
a complex and bidirectional relationship. A higher prevalence of
comorbid physical health conditions (e.g. diabetes and cardiovas-
cular disease) and poorer management of these illnesses contribute
to health inequalities in people with mental illness (Vancampfort
2016a; Ward 2015). People with severe mental illness (SMI) (e.g.
schizophrenia and bipolar disorder) have a particularly high risk of
developing conditions such as diabetes and cardiovascular disease
for reasons associated with the underlying mental disorder, health
risk behaviours (such as physical inactivity, smoking, poor diet)
(Vancampfort 2017) and treatments that increase cardiometabolic
risks and mortality (Liu 2017). Conversely, common mental dis-
orders (e.g. depression and anxiety) are more common in people
with these physical health conditions (Das-Munshi 2007).
Globally, noncommunicable chronic diseases, such as diabetes,
are a major cause of morbidity and mortality (contributing
to 60% of all deaths) (Miranda 2008), including in LMICs
(Lopez 2006). Diabetes is strongly associated with mental illness
(Vancampfort 2015a); for example, around 13% of people with
SMI (Ward 2015) and 9% of people with major depressive dis-
order (Vancampfort 2015b) have diabetes compared to 8.5% of
the general population globally (WHO 2016) and 6% in the UK
(Reilly 2015). Several interventions have been found to be effec-
tive for prevention of type 2 diabetes in the general population
(Merlotti 2014; White 2016). Prevention of diabetes in people
with mental illness is also clearly important. However, due to a
complex combination of psychological, social, and financial barri-
ers, generic interventions to prevent diabetes may not be suitable
for people with mental disorders (Chwastiak 2015). Some of the
additional barriers faced by people with mental illness, not ad-
dressed by generic interventions, include social stigma, poor ac-
cess to medical care (Bradford 2008), fragmentation and lack of
coordination between medical and psychiatric treatment in the
healthcare systems of many countries (Druss 2010), and ‘diag-
nostic overshadowing’, where physical health problems are over-
looked by health professional in the presence of mental illness (Liu
2017). These difficulties compound the challenges of managing
side effects of psychotropic medication and the higher prevalence
of health risk behaviours.
To date, only a limited number of systematic reviews have inves-
tigated the effectiveness of interventions to prevent diabetes for
people with mental illness (McGinty 2016; Taylor 2017). These
reviews have reported that diabetes can be prevented or its on-
set delayed, but included studies were mostly from high-income
countries.
A comprehensive review byMcGinty and others included 33 stud-
ies of interventions for diabetes mellitus in people with SMI. It
found no high-quality evidence for the effectiveness of any inter-
ventions; the best available evidence suggested a potential benefi-
cial effect of metformin on glycated haemoglobin (HbA1c) in this
group (McGinty 2016).
Currently, little is known about the effectiveness of interventions
for preventing diabetes among patients with mental illness in
LMICs. The review by Taylor and colleagues, which focused on
peoplewith SMI, included54 randomised controlled trials (RCTs)
among which only a few were from LMICs (Brazil, India, China,
Iran, Venezuela). However, there was no subgroup analysis for
LMICs and the review excluded people with other forms of men-
tal disorder. Although the review found some evidence for the
effectiveness of pharmacological and nonpharmacological inter-
ventions for improving glycaemic measurements for patients with
SMI (Taylor 2017), we cannot assume that interventions designed
for high-income countries will be suitable or effective for LMICs.
Other similar reviews have investigated the effect of pharmaco-
logical (Maayan 2010; Mizuno 2014), behavioural (Bruins 2014;
Caemmerer 2012; Fernández-San-Martín 2014), or both phar-
macological and behavioural interventions (Faulkner 2007) on
glycaemic measurements in people with SMI. They have also re-
ported that these interventions may be effective, but again have
focused only on people with SMI or those taking antipsychotic
medication, and identified very few studies in LMICs. Moreover,
these studies considered glycaemic effects as a secondary outcome.
A review of the effectiveness of interventions designed to prevent
diabetes in people with any mental disorder, focused on LMICs,
is therefore needed to inform practice and future research for this
population.
Description of the condition
Diabetes is a serious lifelong condition, which is a major health
challenge, with increasing prevalence worldwide showing a partic-
ularly sharp rise in LMICs (Stubbs 2016).
Ninety percent of people with diabetes have type 2 diabetes
(T2DM), a metabolic disorder resulting from a defect in insulin
secretion, insulin action, or both, with disturbances of carbohy-
drates, fat, and protein metabolism. Insulin deficiency leads to hy-
perglycaemia (elevated levels of plasma glucose). Eventually this
may lead to microvascular retinopathy (disease of the retina which
results in impairment or loss of vision), nephropathy (an abnormal
state of the kidney especially one associated with or secondary to
some other pathological process), neuropathy (an abnormal and
usually degenerative state of the nervous system or nerves) and
macrovascular (cardiovascular) complications.
The ‘epidemic’ of diabetes over recent decades has been attributed
to changes in demographics and lifestyle globally (increased life
expectancy, sedentary behaviours, and consumption of high fat
and carbohydrate diets) (Miranda 2008), with LMIC populations
experiencing especially rapid changes, with which health policy
and services have failed to keep pace (Popkin 2002). The risk of
developing diabetes increases with age, obesity, lack of physical
activity, dyslipidaemia (abnormal amount of lipids in the blood),
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and hypertension (ADA 2017), all of which have been adversely
affected by these changes.
There is evidence that mental illness and diabetes comorbid-
ity is very common. A recent systematic review and compar-
ative meta-analysis by Vancompfort and colleagues established
that people with SMI were significantly 1.85 times (95% CI:
1.45 to 2.37) more likely to have T2DM than matched controls
(Vancampfort 2016a). Other systematic reviews and meta-analy-
ses have demonstrated that all SMI diagnosis subgroups, such as
schizophrenia andbipolar disorder, have a higher risk of developing
T2DM than the general population (Pillinger 2017; Stubbs 2015;
Vancampfort 2013; Vancampfort 2015b). There is also good evi-
dence of an association between diabetes and commonmental dis-
orders (Das-Munshi 2007; Moulton 2015; Vancampfort 2016b).
Patients with diabetes have a two- to three-fold increased preva-
lence of depressive disorders (Anderson 2001; Ali 2006) and anx-
iety (Grigsby 2002), although this relationship is likely to be bidi-
rectional (Golden 2008).
Description of the intervention
There are different types of interventions that target the preven-
tion of diabetes; pharmacological, behaviour change and organisa-
tional interventions. Pharmacological interventions aimed at pre-
vention of diabetes in people withmental disorder include diabetes
medication, weight loss medication, combination of diabetes and
weight loss medication, diabetes preventive medication and an-
tipsychotic switching. Behaviour change interventions may target
health risk behaviours, and include patient educationprogrammes,
psychological interventions (e.g. cognitive-behavioural therapy or
counselling), behavioural approaches (e.g.motivational interview-
ing), self-monitoring (including telehealth, internet-based inter-
ventions, andother communication technologies) ormulticompo-
nent interventions (e.g. self-management programmes that com-
bine education and behavioural approaches) (Taylor 2017). Or-
ganisational interventions may include interventions that aim to
improve the delivery of care, such as educating health profession-
als, care planning, or collaborative models of care (Druss 2010).
It may be that there are particular pharmacological, behavioural
and lifestyle, or organisational interventions that would be more
applicable to LMICs as the availability of pharmacological inter-
ventions, resources and organizational structures in LMICs are dif-
ferent from high-income countries. For instance, in LMICs some
drugs may not be available yet, behavioural interventions might
not be feasible due to lack of trained personnel or there may not
be any collaborative models of care in the health system (Koyanagi
2017).
In addition, LMICs are not a homogenous group of countries;
there may be variation as to what is available among LMICs.
There may be an intervention that is available in some LMICs but
not others. For instance, not all pharmacological interventions are
available in every LMIC and there is variability in health care re-
sources and organizational structures (Mate 2013). Therefore, for
this review we will include all pharmacological, behaviour change
and organisational interventions, as it is difficult to define these
a priori, and we do not want to risk excluding effective interven-
tions. Moreover, trials may test interventions that are not currently
available in order to justify their inclusion in subsequent national
formularies.
How the intervention might work
Pharmacological interventions
There are several modes of action for medication in preventing
diabetes. Diabetes medication helps regulate carbohydrate and
fat metabolism, by increasing insulin sensitivity and reducing the
amount of glucose produced and released by the liver. Weight loss
medication or anti-obesity drugs usually act on the gastrointestinal
tract by reducing absorption of dietary fat, stimulate energy ex-
penditure and decrease fat storage, or decrease appetite. Diabetes
combination medications allow patients to switch between treat-
ments depending on clinical response. Switching to or adding an
atypical antipsychotic associated with fewer metabolic side effects
is hypothesised to alleviate weight gain and metabolic abnormal-
ities caused by commonly used antipsychotics such as olanzapine
and clozapine. Other medications may work by enhancing lipid
profile andmetabolic function and regulating or increasing insulin
sensitivity (Taylor 2017).
Behaviour change interventions
These target health risk behaviours using educational, psycholog-
ical, and behavioural approaches, or combinations of these. For
diabetes, there has been a particular focus on self-management
interventions, influenced by several theories of health behaviour
change, including social cognitive theory (Bandura 1986), the the-
ory of reasoned action and planned behaviour (Ajzen 1991), self
regulation theory (Leventhal 1984) and the transtheoretical model
(Prochasta 1997). All of these theories identify concepts that pre-
dict health behaviour (and that may be targeted by behaviour
change interventions), with a primary focus on beliefs, attitudes,
and expectations. For example, a diabetes self-management inter-
vention based on social cognitive theory (Bandura 1986) may seek
to reduce carbohydrate intake by increasing diet-related self-effi-
cacy. These behaviour change techniques are proposed to be the
’active ingredients’ that explain how a self-management interven-
tion might work (McBain 2016).
Organisational interventions
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Organisational capacity building and training programmes in-
crease the efficacy and communication skills of mental health pro-
fessionals or health workers and health services to support preven-
tion of diabetes for people with mental illness (Liu 2017).
Why it is important to do this review
Despite the high prevalence of comorbid mental illness and dia-
betes, there is a lack of research on development of evidence-based
interventions for prevention of diabetes in people with mental dis-
orders in LMICs. This systematic review will summarise the evi-
dence for pharmacological, behaviour change, and organisational
interventions that are targeted at the prevention of diabetes in
people with mental disorders in LMICs.
O B J E C T I V E S
To assess the effects of pharmacological, behaviour change, and
organisational interventions compared to comparator interven-
tion in preventing diabetes among people with mental illness in
LMICs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials evaluating any in-
terventions to prevent type 2 diabetes in people with any men-
tal disorder in LMICs. LMICs will be defined according to the
Development Assistance Committee (DAC) list of all countries
and territories eligible to receive official development assistance
(ODA) (DAC 2017).
Types of participants
We will include studies of adults aged 18 years and over, with any
mental disorder and without diabetes, conducted in LMICs. Stud-
ies that do not explicitly screen for and exclude diabetes at base-
line will not be included. Mental illness diagnosis should be estab-
lished using WHO International Classification of Diseases (ICD)
criteria for mental and behavioural disorders (ICD-10, F20-29
and F30-31, F 32.3, F33.3) (WHO 1992) and/or the Diagnos-
tic and Statistical Manual of Mental Disorders (DSM) (DSM-III,
APA 1980; DSM-III-R, APA 1987; DSM IV, APA 2000; DSM
V, APA 2013) or measures based on these. We will define SMI as
schizophrenia or other psychotic disorders, bipolar disorder, and
depressionwith psychotic features. Commonmental disorders will
include depression, generalised anxiety disorder (GAD), panic dis-
order, phobias, social anxiety disorder, obsessive-compulsive dis-
order (OCD), and post-traumatic stress disorder (PTSD) (NICE
2011). Other mental disorders such as personality disorder and
somatoform disorders will also be included in this review.
Where study populations aremixed (i.e. including people with and
without mental disorder), studies will be included only if people
with mental disorders constitute the predominant population, or
if separate outcome data are provided for them.
Studies involving children or people who already have diabetes,
or studies not conducted in LMICs will not be included in this
review.
To be consistent with changes in the classification of, and diagnos-
tic criteria for diabetes mellitus over the years, studies should use
(and explicitly state) established standard criteria for the diagnosis
of T2DM, valid at the time of the trial commencing (e.g. ADA
1999; ADA 2008; ADA 2017; WHO 1999; WHO 2006).
Types of interventions
Experimental intervention
The review will include any pharmacological, behaviour change
(targeting health risk behaviours), or organisational intervention
that targets the prevention of diabetes in people with any mental
disorder in LMICs.
Pharmacological interventionswill include anymedication-related
interventions, for instance: diabetes medication (e.g. metformin,
pioglitazone); weight loss medication (e.g. amantadine, orlistat,
sibutramine); combination of weight loss and diabetes drugs (e.g.
amantadine with metformin and zonisamide; metformin with
amantadine and zonisamide; metformin with sibutramine); an-
tipsychotic switching (e.g. changing to aripiprazole, quetiapine, or
ziprasidone); or use of other medications purported to prevent di-
abetes. These are examples of potential drugs rather than a defini-
tive list.
Behaviour change interventions commonly target health risk be-
haviours (for example, improving physical activity or diet). This
review will include any behaviour change intervention targeting at
prevention or delaying the onset of diabetes, for example: patient
education programmes, psychological interventions (e.g. cognitive
behavioural therapy or counselling), behavioural approaches (e.g.
motivational interviewing), self-monitoring (including telehealth,
internet-based interventions and other communication technolo-
gies) and, multicomponent interventions (for example, self-man-
agement programmes that combine education and behavioural
approaches).
Organisational interventions includedwill be those that aim to im-
prove the delivery of care, such as educating health professionals,
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care planning, or collaborative models of care. Examples, include
relevant training of any health professionals working with people
with mental illness, nonspecific health worker interventions, com-
munity mental health teams, mass media-delivered interventions,
family interventions, physical health care monitoring, and statu-
tory mental health services intervention.
Comparator intervention
For pharmacological interventions, comparator interventions will
include no treatment (including trials employing wait-list condi-
tions), treatment as usual, placebo drugs or an alternative type of
medication for diabetes prevention.
For behaviour change and organisational interventions we will in-
clude the following comparators: usual care or treatment, atten-
tion or other psychological placebo control, or any alternative be-
haviour change or organisational intervention (as described above
under experimental interventions).
Types of outcome measures
Primary outcomes
Our primary outcome for this review is prevention of diabetes.
A clinical diagnosis of diabetes may be confirmed in the presence
of symptoms by various parameters such as HbA1c, fasting blood
sugar, random blood sugar or, in unclear cases, 2-hour plasma glu-
cose following an oral glucose tolerance test (OGTT). We will ac-
cept diagnoses made using any of these parameters using cut-offs
consistent with those current at the time of the study, as described
in national and international guidance such as WHO (e.g. WHO
2006), National Institute of Health and Care Excellence (NICE)
(e.g. NICE 2015), Diabetes UK (e.g. Diabetes UK 2018), Amer-
ican Diabetes Association (e.g. ADA 2017). Current cut-offs are
as follows: HbA1c ≥ 48 mmol/mol, a fasting blood glucose ≥
7 mmol/L or a random blood glucose ≥ 11.1 mmol/L; and for
OGTT 2-hour glucose≥ 11.1mmol/L (ADA 2017). Conversion
to prediabetes will not be included.
As the adverse primary outcome, we will report drop-out: the
number of participants who drop out of treatment for any reason.
Secondary outcomes
• Body Mass Index (BMI)
• Waist circumference
• Blood pressure
• Cholesterol
• Depression and anxiety measured by a validated scale, e.g.
Patient Health Questionnaire (PHQ 9) (Kroenke 2001),
Generalised Anxiety Disorder assessment (GAD-7) (Spitzer
2006)
• Health related quality of life (evaluated with a validated
generic or disease-specific instrument (Wee 2006), like: 36-Item
Short Form Health Survey (SF-36) (McHorney 1993) or other
validated scale). We will consider language- and culture-adapted
instruments, where these are available
• All-cause mortality, defined as death from any cause
Search methods for identification of studies
Cochrane Common Mental Disorders Controlled
Trials Register (CCMDCTR)
The Cochrane Common Mental Disorders Group (CCMD)
maintains a specialised register of randomised controlled trials, the
CCMDCTR. This register contains over 40,000 reference records
(reports of RCTs) for depression, anxiety, bipolar disorder, eating
disorders, self-harm, and other mental disorders within the scope
of this group. The CCMDCTR is, in part, a studies-based register,
with > 50% of reference records tagged to approximately 12,500
individually PICO-coded study records. Reports of trials for in-
clusion in the register are collated from (weekly) generic searches
of MEDLINE, Embase, and PsycINFO; quarterly searches of the
Cochrane Central Register of Controlled Trials (CENTRAL); and
review-specific searches of additional databases. Reports of trials
are also sourced from international trials registries, drug company
websites, and handsearching of key journals, conference proceed-
ings, and other (non-Cochrane) systematic reviews andmeta-anal-
yses.
Details of CCMD’s core search strategies (used to identify RCTs)
can be found on the Group’s website (Cochrane 2014). In 2016,
the Group’s Specialised Register (CCMDCTR) fell out of date
with the Editorial Group’s move from Bristol to York.
Electronic searches
TheCCMDGroup’s Information Specialist (JW)will cross-search
the CCMDCTR (studies and references register) using the fol-
lowing search terms to find reports of randomised controlled trials
(RCTs): (diabet* or ((glucose or glycemic or glycaemic) near3 con-
trol*)) [all fields]
In addition, JWwill search the following electronic databases with
a comprehensive search strategy, derived from terms related to di-
abetes, mental disorders, LMICs, RCTs and systematic reviews.
Search strategies will be informed by the review of Taylor and col-
leagues (Taylor 2017), theCochrane highly-sensitive search strate-
gies for identifying randomised controlled trials (Lefebvre 2011),
and the AUHE Information Specialist LMIC geographic strategies
(AUHE 2018). The searches will not be limited by date, language,
or publication status. In keeping with the Cochrane MECIR con-
duct standards, we will run a search for retractions and errata once
the included studies have been selected.
5Interventions for preventing type 2 diabetes in adults with mental disorders in low and middle income countries (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
An example of the MEDLINE strategy is provided in Appendix
1.
The search strategy will be translated across to the other databases
listed below, using relevant subject headings and search syntax
appropriate to each resource.
• CINAHL (EBSCO) (1981 to present);
• Cochrane Central Register of Controlled Trials (current
issue);
• Cochrane Database of Systematic Reviews (current issue);
• Embase Classic + Embase (Ovid) (1947 to present);
• Global Health (Ovid) (1910 to present);
• Indian Medlars (indmed.nic.in/) (all available years);
• LILACs (lilacs.bvsalud.org/en/) (all available years);
• Ovid MEDLINE(R) (1946 to present), MEDLINE In-
Process & Other Non-Indexed Citations, MEDLINE Epub
Ahead of Print;
• PsycINFO (Ovid) (1806 to present);
• PubMed (NLM) (1946 to present);
• PakMedNet (www.pakmedinet.com/) (all available years).
Searching other resources
Some grey literature will already have been identified in searches
of the electronic databases listed above (e.g. conference abstracts
in EMBASE, dissertations in PsycINFO, handsearch results in
Cochrane CENTRAL). However, further searching will be under-
taken as listed below.
Grey literature
We will identify grey literature from:
• conference Proceedings Citation Index - Science (Clarivate
Analytics Web of Science) (1990 - present);
• we will search ProQuest Dissertations & Theses Global.
Unpublished studies
Wewill search the following international trial registries to identify
ongoing or unpublished studies (all available years):
• ISRCTN registry (Springer Nature);
• ClinicalTrials.gov (U.S. NIH);
• International Clinical Trials Registry Platform (WHO).
Reference lists
Wewill check the reference lists of all included studies and relevant
systematic reviews to identify additional studies.
Correspondence
We will contact trial authors and subject experts to identify any
additional work which is unpublished or to request additional trial
data.
Data collection and analysis
Selection of studies
We will upload citations and available abstracts of the search re-
sults into Covidence (Covidence 2017) and screen for potential
eligibility in two stages. Covidence is a primary screening and data
extraction software, which helps to streamline the production of
standard intervention reviews. The first stage will involve screen-
ing titles and abstracts to exclude studies that do not meet the
inclusion criteria, carried out independently by three pairs of re-
viewers (MPM and EJP; NT and JT; RA and ZA). Discrepan-
cies will be resolved through discussion, and, where an agreement
cannot be reached, a third reviewer (NS) will be consulted. In the
second stage, we will retrieve the full text of potentially eligible
studies and independently assess them for eligibility, again by three
pairs of reviewers (MPM and EJP; NT and JT; RA and ZA). We
will seek any missing data that could help to assess eligibility by
contacting the corresponding authors. We will present a PRISMA
flow diagram to show the process of trial selection (Liberati 2009).
For studies excluded during this stage, a reason for exclusion will
be recorded. Discrepancies will be resolved by consulting a third
reviewer (NS), who will independently assess the study under con-
sideration. For included studies, we will link multiple reports from
the same study.
Data extraction and management
For trials that fulfil our inclusion criteria, three pairs of review au-
thors (MPM and EJP; NT and JT; RA and ZA) will extract data.
For each study, one reviewer will complete a tailored and pre-pi-
loted data collection form based on the Cochrane Consumers and
Communication Group’s Data Extraction Template for Cochrane
Reviews (http://cccrg.cochrane.org/author-resources), which will
then be checked independently by a second reviewer. We will re-
solve any discrepancies by discussion, or, if required, we will con-
sult a third review author (NS).
To provide information for assessment of study quality and for
evidence synthesis, the following data will be extracted:
1. Study population (including participant inclusion and
exclusion criteria);
2. Country;
3. Setting (primary care, community, secondary care, mental
health care);
4. Study design;
5. Number of intervention groups;
6. Intervention:
i) For pharmacological interventions: class of drug, dose,
frequency, and duration;
ii) For behavior change and organisational interventions:
description of the intervention (including process, target group,
e.g. patients or healthcare professionals, and presence of other
cointerventions), theory (informing intervention design), target
(including strategies, applications, and components), context of
intervention (i.e. primary health facility), provider and mode of
delivery (phone, face-to-face, group, online), intensity (length,
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frequency, and number of contacts), duration (period of time
over which contacts delivered), details about group leader
(demographics, training, professional status, etc.);
iii) Behaviour change techniques. We will categorise
interventions and identify behaviour change techniques using
the ‘template for intervention description and replication’
(TIDieR) checklist (Hoffmann 2014; Hoffmann 2017).
7. Comparison intervention(s).
We will note in the ’Characteristics of included studies’ table if
the study authors did not report outcome data in a usable way.
Where included trials reported outcome data in insufficient de-
tail to include in a meta-analysis, for instance, reporting means
without confidence intervals (CIs) or standard deviations (SDs),
we will contact the study authors to request more information.
Assessment of risk of bias in included studies
We will assess the methodological quality of included randomised
trials using the Cochrane ’Risk of bias’ tool (Higgins 2011a). The
following items will be assessed:
• Sequence generation (i.e. if allocation sequence adequately
generated);
• Allocation sequence concealment (i.e. if allocation
adequately concealed);
• Blinding (i.e. if knowledge of the allocated interventions
adequately prevented during the study);
• Incomplete outcome data (i.e. if incomplete outcome data
adequately addressed);
• Selective outcome reporting (i.e. whether reports of the
study are free of suggestion of selective outcome reporting);
• Other potential sources of bias (i.e. whether the study is
apparently free of other problems that could lead to a high risk of
bias e.g. baseline imbalances, evidence of carry-over in cross-over
trials, comparability of groups in cluster trials).
We will judge each potential source of bias as high, low or unclear
and provide a supporting quotation from the study report together
with a justification for our judgment in the ’Risk of bias’ table.
We will summarise the risk of bias judgements across different
studies for each of the domains listed. Three pairs of review authors
(MPM and EJP; NT and JT; RA and ZA) will independently
rate the certainty of evidence for each outcome. Differences in
assessment will be resolved by discussion or consultation with a
third researcher (NS). Allocation concealment will be used as a
marker of trial quality for the purposes of undertaking sensitivity
analyses.
Measures of treatment effect
For continuous data, we will calculate the mean difference (MD)
with 95% confidence interval (CI). Where trials report the same
outcome using different outcome measures, we will use standard-
ized mean difference (SMD). For binary outcomes, a standard es-
timation of the risk ratio (RR) with a 95% CI will be calculated
using ReviewManager (ReviewManager 2014). In case an eligible
study describes its findings using another effect measure, we will
contact the study authors to obtain data and if we do not receive
the necessary information from trial authors, we will impute these
values.
Unit of analysis issues
We will take into account the level at which randomisation oc-
curred, with respect to cross-over trials, cluster RCTs, andmultiple
observations for the same outcome.
We will attempt to reanalyse cluster-RCTs that have not appropri-
ately adjusted for potential clustering of participants within clus-
ters in their analyses by inflating the variance of the intervention
effects by the design effect. We will obtain estimates of the in-
tracluster correlation coefficient (ICC) in order to estimate the
design effect through contact with authors, or impute them by
using either estimates from other included trials that report ICCs
or external estimates from empirical research (e.g. Bell 2013).
In the case of multiple intervention groups, we will analyse each
intervention group separately against the control group and the
sample size for the control group will be divided proportionately
across each intervention group. Where results are reported at mul-
tiple time points in the studies, we will analyse each outcome at
predefined periods of follow-up in separate meta-analyses. We will
group time points as follows: less than six months, and six months
or more. We have selected these time points as representing time
frames in which a difference in the likelihood of responding could
be expected.
If more than one comparison from the same trial is eligible for
inclusion in the samemeta-analysis, we will either combine groups
to create a single pairwise comparison or appropriately reduce the
sample size so that the same participants do not contribute data to
the meta-analysis more than once (i.e. splitting the ’shared’ group
into two or more groups), although we acknowledge this will not
account for correlation arising from the same set of participants
being in multiple comparisons (Higgins 2011a) .
Dealing with missing data
We will carefully evaluate important numerical data such as
screened and randomly assigned participants as well as intention-
to-treat, and as-treated and per-protocol populations. We will in-
vestigate attrition rates (e.g. dropouts, losses to follow-up, with-
drawals), and we will critically appraise issues concerning missing
data.
Data will be analysed primarily using the intention-to-treat (ITT)
principle. However, if the included studies do not provide enough
detail to allow for an ITT analysis, and where included trials do
not report means and SDs for outcomes, data will be requested
from study authors. However, if we do not receive the necessary in-
formation from trial authors, we will impute these values (Higgins
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2011a; Higgins 2011b). We will investigate the impact of impu-
tation on meta-analyses by performing sensitivity analyses.
Assessment of heterogeneity
Clinical heterogeneity will be assessed through the description of
the setting, baseline measures, and intervention approach used in
each study. In the case of obvious clinical heterogeneity we will
not pool the data and the studies will be described.
Statistical heterogeneity will be assessed using theChi2 test and the
I2 statistic. The Chi2 test will be considered statistically significant
if P ≤ 0.10. If heterogeneity exists between studies (I2 ≥ 50%)
for the primary outcome, reasons for the heterogeneity will be
explored. Our exploration will follow the Cochrane Handbook
guidance (Deeks 2011), which suggests the following guidance for
interpretation of the I2 statistic:
• 0 to 40%: might not be important
• 30% to 60%: may represent moderate heterogeneity
• 50% to 90%: may represent substantial heterogeneity
• 75% to 100%: considerable heterogeneity
We will take into account (i) magnitude and direction of effects
and (ii) strength of evidence for heterogeneity (e.g. the P value
from the chi2-squared test, or a confidence interval (CI) for I2)
when interpreting the I2 statistic.
Assessment of reporting biases
If more than 10 studies that investigate a particular outcome are
identified for inclusion in this review, funnel plots will be used to
assess publication biases. Quantitative analysis of publication bias
such as the Egger test will also be conducted.
Data synthesis
Data from individual trials will be combined by meta-analysis if
the interventions, outcomes, and patient groups are sufficiently
similar (determined by expert consensus).
Data will not be pooled for meta-analysis if we detect a high degree
of heterogeneity (I2 > 75%). Where data are pooled, a random-
effects model will be used as a consideration of the heterogeneity
of populations.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses, based on
characteristics of the population or intervention that might be
expected to influence the primary outcome:
• Age (65 years and over) and gender, which may influence
risk of diabetes;
• Type of mental disorder (SMI versus other mental disorder;
people with SMI have additional risk factors for diabetes e.g. side
effects of antipsychotic medication);
• Prospective identification of diabetes using a robust
approach to diagnosis e.g. HbA1c or fasting blood sugar, versus
studies using retrospective records, random blood glucose
testing, or both;
• Intervention duration (less than three months versus three
months or more; intensity of the intervention may influence
outcomes);
• Duration of follow-up (less than three months versus three
months or more; this is likely to influence detection of
outcomes).
Sensitivity analysis
For outcomes where two or more studies are available to include
in a meta-analysis, we will perform sensitivity analyses to explore
the influence of the following factors (where applicable) on effect
sizes:
• effect of risk of bias: studies that have not used allocation
concealment will be excluded;
• effect of large trials: large trials will be excluded to establish
the extent to which they dominate the results;
• effect of data imputation: trials where missing data have
been imputed will be excluded.
We have restricted the planned sensitivity analyses to these as they
are likely to be the most relevant in influencing findings.
’Summary of findings’ table
We will prepare ’Summary of findings’ tables to summarise key
findings of this review. We will report the outcomes (including
adverse outcomes) and present standardised effect size estimates
and 95% CIs, using the GRADE approach to assess the overall
quality of the evidence supporting each outcome. GRADE criteria
take into account issues related not only to internal validity (risk
of bias, inconsistency, imprecision, publication bias) but also to
external validity, such as directness of results.Wewill useGRADE-
proGDT to create our ’Summary of findings’ tables (GRADEpro
2015), and follow standard methods as described in the Cochrane
Handbook for Systematic Reviews of Interventions to prepare our
’Summary of findings’ table (Schünemann 2017). For each of our
main comparisons, the following outcomes (measured up to 12
months) will be included:
• Diabetes diagnosis determined by HbA1c or fasting blood
glucose or measured via other diagnosis method current at the
time the study was conducted);
• Drop-out;
• BMI;
• Health-related quality of life;
• Mortality.
The definitive list of comparisons to be included in the ‘Summary
of findings’ tables will be agreed with clinicians once the categories
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of interventions are known, guided by clinical relevance. This is
because the range of interventions to be included is broad, and at
this stage, we cannot know which categories of intervention will
be identified by the review.
’Summary of findings’ tables will be created after we have entered
data into RevMan (ReviewManager 2014), written up our results,
and conducted the ’Risk of bias’ assessment. However, the ’Sum-
mary of findings’ table will be created before writing our discus-
sion, abstract, and conclusions, to allow the opportunity to con-
sider the impact of the risk of bias in the studies contributing to
each outcome upon the mean treatment effect and our confidence
in these findings.
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A P P E N D I C E S
Appendix 1. Search strategy
Database: Ovid MEDLINE(R) <1946 to July Week 5 2018>
Search Strategy:
--------------------------------------------------------------------------------
1 diabet*.tw,kf. (568532)
2 exp Diabetes mellitus/ (391230)
3 Glucose Tolerance Test/ (33313)
4 Glycated Hemoglobin A/ (31364)
5 (noninsulin*-depend* or non-insulin*-depend* or noninsulin*depend* or non-insulin*depend*).tw,kf. (12200)
6 (fasting glucose or plasma glucose or glucose tolerance test* or (glyc?emic adj2 control*)).tw,kf. (87693)
7 (HbA1c or A1C or A1c or Hb1c or ((glycated or glycosylated) adj h?emoglobin?)).tw,kf. (46468)
8 (IDDM or NIDDM or MODY or T1DM or T2DM or T1D or T2D).tw,kf. (44357)
9 or/1-8 (663621)
10 exp Diabetes Insipidus/ (7654)
11 diabet* insipidus.tw,kf. (8395)
12 10 or 11 (10371)
13 9 not 12 [DIABETES] (654765)
14 exp Mental Disorders/ (1140872)
15 exp Behavioral Symptoms/ (326828)
16 (mental or mentally or psychiatr* or psycho* or depressi* or depressed or MDD or anxi* or phobia or phobic or agoraphobi* or
dysthymi* or ADNOS).tw,kf. (1315284)
17 (schizo* or hebephrenic* or oligophreni* or akathisi* or acathisi* or neuroleptic-induc*).tw,kf. (137538)
18 (tardiv* adj dyskine*).tw,kf. (4218)
19 (movement adj5 (disorder or disorders)).tw,kf. (16677)
20 (somatoform or somatiz* or somatis* or hysteri* or briquet ormultisomat* ormulti somat* orMUPs ormedically unexplained).tw,kf.
(13094)
21 ((dissociative adj3 (disorder* or reaction*)) or dissociation).tw,kf. (104569)
22 (affective* adj (disorder? or disease? or illness* or symptom?)).tw,kf. (18268)
23 (PTSD or psychological trauma or psychotrauma* or combat disorder? or war disorder?).tw,kf. (22286)
24 ((post-trauma* or posttrauma*) adj3 (stress* or disorder?)).tw,kf. (29425)
25 ((stress or cognitive or cognition or personality or impulse control or mood or paranoid or psychotic or neurologic* or nervous or
nervous system or eating) adj (disorder? or illness* or disease?)).tw,kf. (140175)
26 ((bipolar or behavio?ral or obsessive or compulsive or panic or mood or delusional) adj (disorder? or illness* or disease?)).tw,kf.
(63498)
27 (trichotillomani* or OCD or obsess*-compulsi* or GAD or stress reaction? or acute stress or neuros#s or neurotic).tw,kf. (50701)
28 (stress syndrome? or distress syndrome? or pain disorder? or dementia or alzheimer? or epilepsy).tw,kf. (312640)
29 ((substance abuse or “substance use” or drug abuse or “drug use”) adj2 disorder?).tw,kf. (14220)
30 (personality adj2 disorder?).tw,kf. (18800)
31 (sleep? adj2 (disorder? or syndrome?)).tw,kf. (23532)
32 or/14-31 [ALL MENTAL DISORDERS] (2432067)
33 Developing Countries/ (71059)
34 (low* income* adj3 (countr* or nation* or economy or economies)).tw,kf. (6240)
35 (middle income* adj3 (countr* or nation* or economy or economies)).tw,kf. (13271)
36 (low* middle adj3 (countr* or nation* or economy or economies)).tw,kf. (1294)
37 (LMIC or LMICs).tw,kf. (3055)
38 ((LIC or LICs) adj3 (countr* or nation* or economy or economies)).tw,kf. (139)
39 “transition* countr*”.tw,kf. (283)
40 ((underserved or “under served” or deprived or poor*) adj3 (country or countries or nation? or economy or economies)).tw,kf.
(4809)
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41 ((Developing or “under developed” or underdeveloped or “less* developed” or “third world”) adj3 (country or countries or nation?
or economy or economies)).tw,kf. (89058)
42 ((Developing or “under developed” or underdeveloped or “less* developed”) adj2 world).tw,kf. (8295)
43 ((Africa* not “African American*”) or (Asia* not “Asian American*”)).ti,ab,in,kf. (340834)
44 (Afghanistan* or Albania* or Algeria* or Angola* or Anguilla* or Antigua or Barbuda or Argentin* or Armenia* or Aruba* or
Azerbaijan* or Bahamas or Bahrain* or Bangladesh* or Barbados or Belarus* or Belize* or Benin* or Bermuda* or Bhutan* or Bolivia*
or Bosnia* or Herzegovina or Borneo or Botswana* or Brazil* or Brunei* or Bulgaria* or “Burkina Faso” or Burundi*).ti,ab,in,kf.
(475308)
45 (Cambodia* or Cameroon* or “Cape Verde*” or “Cabo Verde*” or Caribbean* or “Cayman Is*” or Chad or Chile* or China or
Chinese or (Colombia* not “British Colombia*”) or Comoros or Congo or “Cook Island*” or “Costa Rica*” or “ivory coast” or “cote
d’ivoire” or Croat* or Cuba* or Cyprus or Cypriot* or Czech* or Djibouti* or Dominica*).ti,ab,in,kf. (1670756)
46 (Ecuador* or Egypt* or “El Salvador” or Eritrea* or Estonia* or Ethiopia* or “Falklands Is*” or Fiji* or Gabon* or Gambia* or
Ghana* or Gibralta* or Grenada* or Guatemala* or Guinea* or Guyana* or Haiti* or Hondura* or “Hong Kong*” or Hungary or
Hungarian* or India or (Indian? not “American Indian?”) or Indonesia* or Iran* or Iraq* or Israel*).ti,ab,in,kf. (1304826)
47 (Jamaica* or Jordan* or Kazakhstan* or Kenya* or Kiribati* or Korea* or DPRK or Kosovo* or Kuwait* or Kyrgyz* or “Lao PDR”
or “Lao People*” or Laos or Laotian or Latvia* or Lebanon or Lebanese or Lesotho or Liberia* or Libya* or Lithuania*).ti,ab,in,kf.
(482480)
48 (Macao* or Macau or Macedonia* or Madagasca* or Malawi* or Malaysia* or Maldives or Mali or Malta or Maltese or “Marshall
Islands” or Mauritania* or Mauritius or Mayotte* or Melanesia* or Mexico or Mexican? or Micronesia* or Moldova* or Mongolia* or
Montenegro* or Morocco or Moroccan? or Mozambique* or Myanmar*).ti,ab,in,kf. (262490)
49 (Namibia* or Nauru* or Niue* or Nepal* or “Netherlands Antilles*” or “Dutch Antilles” or “New Caledonia*” or Nicaragua* or
Niger or Nigeria* or Oman* or Pakistan* or Palau* or Palestin* or Panama or “Papua New Guinea*” or Paraguay or Peru* or Peruvian*
or Philippines* or Pilipin* or Filipin* or Poland or Polish or Polynesia* or Qatar* or Romania* or Russia* or Rwanda*).ti,ab,in,kf.
(498654)
50 (Samoa* or “Sao Toms*” or Principe* or Saudi or Senegal* or Serbia* or Seychelles or “Sierra Leone” or Singapor* or Slovak* or
Sloven* or “Solomon Islands” or Somalia* or “Sri Lanka*” or “S* Kitts and Nevis” or “S* Lucia” or “S* Helena” or “S* Vincent and the
Grenadines” or “South America*” or Sudan* or Suriname* or Swaziland* or Syria*).ti,ab,in,kf. (297323)
51 (Taiwan* or Taipei* or Tajikistan* or Tanzania* or Thai* or Timor* or Tobago or Togo or Tokelau or Tonga or Trinidad or Tunisia* or
Turkey or Turkish or Turkmenistan* or “Turks and Caicos” or Tuvalu* or Uganda* or Ukrain* or “United Arab Emirates” or Uruguay*
or Uzbekistan* or Vanuatu* or Venezuela* or Vietnam* or “Virgin Is*” or “Wallis and Futuna” or Futuna or “West Bank” or Gaza or
Yemen* or Zambia* or Zimbabw*).ti,ab,in,kf. (639017)
52 exp Africa/ (239986)
53 west indies/ or “antigua and barbuda”/ or bahamas/ or barbados/ or “british virgin islands”/ or cuba/ or dominica/ or dominican
republic/ or grenada/ or haiti/ or jamaica/ or saint lucia/ or “saint vincent and the grenadines”/ or “saint kitts and nevis”/ or “trinidad
and tobago”/ (18381)
54 central america/ or costa rica/ or el salvador/ or guatemala/ or honduras/ or nicaragua/ or exp panama/ or mexico/ (47882)
55 exp south america/ (142190)
56 exp Atlantic Islands/ (1484)
57 asia/ or exp asia, central/ or exp asia, southeastern/ or exp asia, western/ or far east/ or exp china/ or exp korea/ or Taiwan/ (574049)
58 exp Middle East/ (119186)
59 pacific islands/ or exp melanesia/ or micronesia/ or palau/ or polynesia/ or exp samoa/ or tonga/ (12922)
60 exp Europe, Eastern/ or Cyprus/ or Malta/ or Gibraltar/ (170978)
61 Georgia.ti,ab. not Georgia/ (5171)
62 (Montserrat not (Spain or Espana)).ti,ab. (114)
63 or/33-62 [LMICs based on ODA DAC flows 2003 - 2020] (5556279)
64 randomized controlled trial.pt. (471052)
65 controlled clinical trial.pt. (92742)
66 randomized.ab. (425782)
67 placebo.ab. (192990)
68 clinical trials as topic.sh. (185222)
69 randomly.ab. (299878)
70 trial.ti. (189624)
71 64 or 65 or 66 or 67 or 68 or 69 or 70 (1180572)
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72 exp animals/ not humans.sh. (4512703)
73 71 not 72 [RCTs - Cochrane RCT2 Precision Maximising] (1086053)
74 13 and 32 and 63 and 73 [Diabetes + Mental Illness + LMICs + RCTs] (905)
75 13 and 32 and 63 (12134)
76 limit 75 to systematic reviews (427)
77 74 or 76 [Diabetes + Mental Illness + LMICs + RCTs or Systematic Reviews] (1273)
78 (exp Child/ or Adolescent/ or exp Infant/) not exp Adult/ (1769038)
79 77 not 78 [Final Search child-only studies removed] (1232)
C O N T R I B U T I O N S O F A U T H O R S
Drafting of protocol: MPM, EJP, JW, JT, RA, NT, ZA, BS, RC, NS
Search strategy: JW, RC, NS
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None known.
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